Objective: To investigate the mechanism of dexmedetomidine (Dex) in improving brain damage induced by cerebral ischemia-reperfusion injury in rats.
Methods: Rats were randomly divided into a sham operation group, ischemia-reperfusion group, Dex group, piracetam group, and yohimbine + Dex group, with 12 rats per group. 2,3,5-Triphenyltetrazolium chloride staining was used to analyze cerebral infarct size. Hematoxylin-eosin staining and immunohistochemistry were used to observe brain damage caused by ischemia-reperfusion. Cognitive and memory functions was detected by Morris water maze test, and the expression of phosphorylated extracellular signal-regulated kinases 1 and 2 (ERK1/2) and phosphorylated cyclic adenosine monophosphate response element binding protein (CREB) were measured by Western blot.
Results: Cognitive dysfunction was improved in the Dex group and the piracetam group compared with the ischemia-reperfusion group. Compared with the ischemia-reperfusion group, infarct size and neuronal cell death rates were decreased in the Dex group and the piracetam group. The expression of phosphorylated ERK1/2 and phosphorylated CREB in the Dex group was increased, whereas the expression of phosphorylated ERK1/2 and phosphorylated CREB in the yohimbine + Dex group was lower than in the Dex group (P < 0.05).
Conclusions: Dex improved ischemic brain damage by promoting signal transduction of the ERK/CREB pathway, which may provide new ways for clinical treatment of cerebral ischemia-reperfusion injury.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wneu.2019.03.232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy analysis of intratympanic injection of dexamethasone at different concentrations for the treatment of unilateral idiopathic sudden sensorineural hearing loss.
Am J Otolaryngol
January 2025
Department of Otolaryngology-Head and Neck Surgery, Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Yangzhou, Jiangsu Province 225001, PR China. Electronic address:
Objective: Our study tried to evaluate and compare the therapeutic efficacy of intratympanic injection of dexamethasone (DEX) at different concentrations for the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL).
Methods: A prospective randomized controlled study was conducted on 203 patients with unilateral ISSNHL. Patients were divided into four groups: the control group (n = 47, systemic treatment only), the high-concentration group (n = 51, intratympanic injection of DEX 20 mg/ml), the medium-concentration group (n = 55, 10 mg/ml), and the low-concentration group (n = 50, 5 mg/ml).
Colon delivery of agomelatine nanoparticles in the treatment of TNBS induced ulcerative colitis.
Drug Deliv Transl Res
January 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran.
Agomelatine is an atypical antidepressant with a long half-life and the mechanism of action similar to melatonin. Agomelatine is a strong antioxidant and its anti-inflammatory effect has been reported in many studies. The current study aimed to evaluate the anti-inflammatory effect of agomelatine loaded in targeted nanoparticles (NPs) in an experimental colitis model induced by trinitrobenzene sulfonic acid (TNBS).
View Article and Find Full Text PDFIntratympanic administration of dexamethasone attenuates radiation induced damage to middle ear mucosa.
Sci Rep
January 2025
Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea.
Radiotherapy (RTx) is a highly effective treatment for head and neck cancer that can cause concurrent damage to surrounding healthy tissues. In cases of nasopharyngeal carcinoma (NPC), the auditory apparatus is inevitably exposed to radiation fields and sustains considerable damage, resulting in dysfunction. To date, little research has been conducted on the changes induced by RTx in the middle ear and the underlying mechanisms involved.
View Article and Find Full Text PDFEfficacy of Dexamethasone as an Adjuvant for Scalp Nerve Blocks to Prolong Analgesia: A Prospective, Double-Blind, Randomized Controlled Study.
J Pain Res
January 2025
Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Background: Scalp nerve blocks (SNB) may significantly reduce post-craniotomy pain (PCP) but only for a short period of time. Dexamethasone, as an adjuvant to local anesthetics, was reported to prolong the analgesia duration of never block; however, the addition of dexamethasone to SNB is rare. We therefore tested the hypothesis that dexamethasone as an adjuvant to bupivacaine in SNB is positive after craniotomy.
View Article and Find Full Text PDFEfficacy and Safety of Adding 1μg/Kg Dexmedetomidine to 20ml Bupivacaine in Supraclavicular Brachial Plexus Block: A Randomized Trial.
Curr Drug Saf
January 2025
Anesthesiology, Surgical Intensive Care and Pain Medicine Department, Faculty of Medicine, Kafr-El Sheikh University, Kafr-El Sheikh, Egypt.
Background: For surgical procedures of the upper limbs, ultrasound-guided supraclavicular brachial plexus block (SCBPB) represents a safe substitute for general anesthesia. The present study evaluated the effectiveness and safety of incorporating 1μg/kg dexmedetomidine (DEX) into 20 ml bupivacaine, as opposed to using 20 ml and 30 ml bupivacaine without additives, in SCBPB.
Methods: This randomized, controlled, double-blind study included 75 patients assigned to elective upper-limb surgery under the mid-humerus level.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!